EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

The Real-World Safety and Effectiveness of Rituximab in Preventing Antibody-Mediated Rejection in ABO-Incompatible Liver Transplantation: All-Case Postmarketing Surveillance in Japan

Mana Kobayashi, Junko Sakamoto, Takashi Ando

Transplantation Proceedings · 2026-07 · 58 (6) · 1104-1113

DOI: 10.1016/j.transproceed.2026.05.014 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Transplantation Proceedings, 2026-07. Verfasst von Mana Kobayashi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacovigilance and Quality Assurance Department, Zenyaku Kogyo Co Ltd, Bunkyo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Rituximab, Liver Transplantation, Graft Rejection, ABO Blood-Group System. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chugai Pharmaceutical, Nippon Zenyaku Kogyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabLiver TransplantationGraft RejectionABO Blood-Group SystemIsoantibodiesProduct Surveillance, PostmarketingJapanBlood Group IncompatibilityGraft SurvivalPreoperative CareAllograftsLiverImmunosuppressive AgentsSurvival RateHumansMaleFemaleAdolescentYoung AdultAdultMiddle AgedAgedTreatment Outcome

Substanzen

RituximabABO Blood-Group SystemIsoantibodiesImmunosuppressive Agents

Autor:innen und Institutionen

  • Pharmacovigilance and Quality Assurance Department, Zenyaku Kogyo Co Ltd, Bunkyo-ku, Tokyo, Japan.
  • Pharmacovigilance and Quality Assurance Department, Zenyaku Kogyo Co Ltd, Bunkyo-ku, Tokyo, Japan. Electronic address: takashi_ando@mail.zenyaku.co.jp.

Förderung

  • Chugai Pharmaceutical
  • Nippon Zenyaku Kogyo

Zitieren

APA

Kobayashi, M., Sakamoto, J., & Ando, T. (2026). The Real-World Safety and Effectiveness of Rituximab in Preventing Antibody-Mediated Rejection in ABO-Incompatible Liver Transplantation: All-Case Postmarketing Surveillance in Japan. Transplantation Proceedings, 58(6), 1104-1113. https://doi.org/10.1016/j.transproceed.2026.05.014

Vancouver

Kobayashi M, Sakamoto J, Ando T. The Real-World Safety and Effectiveness of Rituximab in Preventing Antibody-Mediated Rejection in ABO-Incompatible Liver Transplantation: All-Case Postmarketing Surveillance in Japan. Transplantation Proceedings. 2026;58(6):1104-1113. doi:10.1016/j.transproceed.2026.05.014

BibTeX
@article{Kobayashi2026,
  author = {Kobayashi, Mana and Sakamoto, Junko and Ando, Takashi},
  title = {The Real-World Safety and Effectiveness of Rituximab in Preventing Antibody-Mediated Rejection in ABO-Incompatible Liver Transplantation: All-Case Postmarketing Surveillance in Japan},
  journal = {Transplantation Proceedings},
  year = {2026},
  volume = {58},
  number = {6},
  pages = {1104--1113},
  doi = {10.1016/j.transproceed.2026.05.014}
}
Kostenlos starten →